Ah, the financial markets. A bastion of rational thought, predictable trends, and calm, calculated decisions. Unless, of course, Donald J. Trump decides to weigh in. Then, much like a toddler with a remote control, the market’s channel-surfing becomes erratic, unpredictable, and occasionally, surprisingly entertaining. The past few weeks have offered a masterclass in this particular brand of market whiplash, as pronouncements from the former (and potentially future) president sent sectors reeling, then recovering, then perhaps just shrugging in collective bewilderment. From the sudden benevolence towards Big Pharma to the existential dread of renewed nuclear testing, and a Supreme Court showdown over tariffs, investors have once again found themselves on a ride where the only constant is the unexpected.
The Prescription for Volatility: Pharma’s Wild Ride
Just when you thought you had a handle on the pharmaceutical industry’s relationship with the Trump administration, a new plot twist emerges. For years, the rallying cry against “exorbitant drug prices” has been a staple. So, imagine the collective gasp (or perhaps a knowing nod from seasoned Trump-watchers) when, on November 6, 2025, the former president announced landmark deals with pharmaceutical giants Eli Lilly and Novo Nordisk. The stated goal? To slash prices for their blockbuster obesity drugs, Wegovy and Zepbound, and expand Medicare and Medicaid coverage through a new direct-to-consumer platform, TrumpRx.gov.
The immediate market reaction was, in typical fashion, a study in contrasts. On the day of the announcement, Novo Nordisk (NVO) shares managed to climb around 3% in pre-market trading, with Eli Lilly (LLY) also trading marginally higher, as investors anticipated the details of the deal. One might conclude that lower prices and expanded access are, surprisingly, good for business. However, rewind just a few weeks to October 16-17, 2025, when Trump’s mere comments about *potential* price reductions sent shivers down Wall Street’s spine. On October 17, Novo Nordisk shares plummeted nearly 6% to 344.7 Danish crowns, hitting a three-week low, while Eli Lilly dropped a respectable 4% in pre-market trading. Apparently, the threat of price cuts is far more terrifying than the actual implementation, especially when it comes with the sweet, sweet promise of expanded government coverage.
Analysts, ever the voice of reason (or at least, explanation), offered their interpretations of this pharmaceutical pivot. Evan Seigerman, an analyst at BMO Capital, suggested that the deal could disproportionately benefit Eli Lilly, solidifying its lead in the burgeoning GLP-1 market. His reasoning? The expanded government coverage would more than offset any decline in net pricing. Deutsche Bank analysts echoed this sentiment, viewing the deal as a potential catalyst for LLY‘s growth, envisioning a $150 monthly cap unlocking access for up to 15 million Americans. Meanwhile, JPMorgan analysts, after the initial October jitters, calmly stated that Trump’s comments were “in line with our expectations” for Novo Nordisk‘s GLP-1 portfolio, seeing “no downside to our numbers” despite the lower price points. It seems the market, like a well-trained dog, eventually learned to fetch the positive spin, even if it initially cowered at the command. Adding another layer of corporate maneuvering, Eli Lilly is reportedly leveraging these talks to push for an expedited FDA review for its oral GLP-1 pill, Orforglipron. Because why just lower prices when you can also fast-track your next blockbuster?
Tariff Tantrums and Judicial Jitters
Beyond the realm of weight-loss drugs, another significant market mover has been the ongoing saga of Trump’s tariff authority. On November 5-6, 2025, the U.S. Supreme Court found itself in the unenviable position of debating whether a president can unilaterally impose sweeping tariffs under the International Emergency Economic Powers Act (IEEPA). The irony, of course, is that both conservative and liberal justices appeared skeptical, questioning whether such broad powers truly align with constitutional principles or if they infringe upon Congress’s inherent authority to levy taxes. One can almost hear the collective sigh of relief from global trade partners at the prospect of a judiciary potentially reining in the executive’s more impulsive economic tendencies.
The market’s reaction to this judicial wrestling match was, predictably, a bit of a head-scratcher. On November 6, the S&P 500 (SPX) dipped 0.2%, the Dow (DJI) remained flat, and the Nasdaq Composite (COMP:IND) edged down 0.3% as traders anxiously awaited updates. US stock futures had also shown a slight decline on Wednesday evening (November 5), with S&P 500 futures down 0.2%, Nasdaq 100 futures down 0.3%, and Dow Jones Industrial Average futures slipping 62 points (0.1%). However, in a twist that only a Trump-era market could deliver, earlier on Wednesday afternoon (November 5), the stock market actually surged. The Dow Jones Industrial Average (DJI) rose 300 points and the S&P 500 (SPX) gained nearly 1% as selling pressure on tech stocks eased. This rally was reportedly fueled by the *hope* that the Supreme Court’s skeptical stance might lead to the overturning of tariffs. So, the market dips on uncertainty, then rallies on the *possibility* of a policy reversal. It’s enough to make a seasoned investor consider a career in meteorology.
The implications of a ruling against Trump’s tariff authority are, shall we say, significant. Experts suggest it could trigger refunds of billions in previously collected duties, potentially around $90 billion of the $195 billion collected in fiscal 2025. Cory Johnson, Chief Market Strategist at Epistrophy Capital Research, optimistically dubbed this a potential “corporate cash stimulus”. Of course, the alternative is that new tariffs, perhaps with different justifications, could simply take their place, ensuring that market uncertainty remains a growth industry.
Nuclear Ambitions and Defense Dividends
Just when the market thought it had enough on its plate, Trump decided to add a dash of geopolitical drama. He announced a grand “denuclearization plan” with China and Russia, only to immediately follow it up with instructions to the “Department of War” to resume nuclear weapons testing. Not to be outdone, Russian President Vladimir Putin promptly ordered Russia to resume its own nuclear testing in response. One might almost suspect a coordinated effort to keep the global anxiety levels at a healthy simmer.
However, much like a poorly executed magic trick, the immediate threat was quickly clarified. U.S. Energy Secretary Chris Wright stepped in on November 2 to explain that the planned American tests would be “non-critical explosions” or “subcritical tests,” meaning no actual nuclear detonations. A sigh of relief, perhaps, but the initial chest-thumping was enough to send a clear signal to a particular corner of the market: defense stocks. Companies like Lockheed Martin (LMT), Northrop Grumman (NOC), BWX Technologies (BWXT), RTX, General Dynamics (GD), and Boeing (BA) are all anticipated to benefit from this renewed focus on defense spending. Indeed, the iShares U.S. Aerospace & Defense ETF (ITA) has already seen a robust 50% increase in 2025. Because nothing says “peace through strength” quite like a booming defense sector.
Truth Social: The Ultimate Meme Stock?
No analysis of Trump’s market impact would be complete without a nod to his digital soapbox, Truth Social, and its publicly traded parent, Trump Media & Technology Group (DJT). The stock’s performance has been less a steady climb and more a series of dramatic cliff dives and improbable bounces, driven less by traditional fundamentals and more by the sheer force of political will and online sentiment.
On November 5, 2025, DJT managed a modest gain of 2.53%, closing at $14.17 after opening at $13.82. A small victory, perhaps, but one quickly overshadowed by its broader trajectory. The stock has fallen in 6 of the last 10 trading days, shedding 9.51% over that period. Flashback to April 3, 2024, and DJT tumbled a staggering 21%, closing at $48.66, a precipitous 39% plunge from its March 26 high of $79.38. By August 14, 2024, it had lost over 50% of its value since its IPO, dropping to $23.54. As of October 2025, the stock hovered around $15.99, with forecasts for December 5, 2025, predicting a further drop to $7.83 per share. Analyst sentiment is, unsurprisingly, bearish, with the “Fear & Greed Index” firmly planted in “Fear” territory at 39. It seems even the most ardent supporters struggle to justify its valuation based on anything resembling traditional business metrics.
Yet, the power of Trump’s direct communication cannot be entirely dismissed. In a remarkable demonstration of market influence on April 10, 2025, a Truth Social post from Trump, advising “GREAT TIME TO BUY!!!”, preceded a 90-day suspension of most tariffs. This move propelled the S&P 500 (SPX) to climb by 9.5%, restoring approximately $4 trillion in market value. It’s a stark reminder that in the age of social media, a single post can, at times, be more impactful than a Federal Reserve announcement. The market, it seems, is always listening, even if it’s often left wondering what exactly it just heard.
In conclusion, the financial markets under the influence of Donald Trump remain a captivating, if not entirely coherent, spectacle. From the sudden embrace of pharmaceutical giants to the judicial tightrope walk over trade policy and the ever-present specter of nuclear brinkmanship, investors are treated to a constant stream of policy flip-flops and pronouncements that defy conventional wisdom. The only certainty is uncertainty, and the only predictable element is the sheer unpredictability. For those seeking a calm, steady investment journey, perhaps a nice index fund and a strong cup of chamomile tea are in order. For everyone else, grab your popcorn; the show is far from over.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.